Open AccessZoledronic Acid for the Treatment of Children With Refractory Central Giant Cell Granuloma
Author(s) -
May Chien,
Leo Mascarenhas,
Jeffrey A. Hammoudeh,
Rajkumar Venkatramani
Publication year - 2015
Publication title -
journal of pediatric hematology/oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.388
H-Index - 78
eISSN - 1536-3678
pISSN - 1077-4114
DOI - 10.1097/mph.0000000000000380
Subject(s) - medicine , zoledronic acid , central giant cell granuloma , refractory (planetary science) , bisphosphonate , pediatrics , dermatology , surgery , giant cell , pathology , osteoporosis , physics , astrobiology
There are no approved medical therapies for the treatment of pediatric central giant cell granuloma (CGCG), a benign but potentially aggressive tumor of the jaw. Zoledronic acid (ZA), a third-generation bisphosphonate, has been used in CGCG occurring in adults. We describe 4 patients with CGCG treated with ZA, 3 of whom achieved resolution of disease up to 4 years of follow-up. Our experience suggests that ZA may be considered as treatment for pediatric CGCG.